Heart Tumor Market size was valued at USD 1.1 billion in 2024 and is projected to reach USD 2.3 billion by the end of 2037, rising at a CAGR of 6.5% during the forecast period, i.e., 2025-2037. In 2025, the industry size of heart tumor is evaluated at USD 1.2 billion.
The heart tumor market is observing remarkable growth due to improving diagnostic imaging and a growing emphasis on early detection and personalized cardiac care. With diagnostics being increasingly effective, companies are introducing new offerings that will help bring accuracy and speed to cardiac imaging. For example, in June 2024, Philips introduced the Philips Cardiac Workstation aimed at enhancing diagnostic cardiology and patient care in the Middle East, Africa, and Europe. This further illustrates the pace at which the market is moving in developing new diagnostic platforms that could enable swift clinical decisions, particularly in instances where governments and health entities are emphasizing cardiac care and ensuring investments in the latest technologies.
Governments and health centers around the world encourage heart tumor research and diagnosis through funding programs or creating public health programs that target cardiovascular diseases. This is reflected in more funds being allocated toward diagnosing cancer and heart diseases, accompanied by increased rates of early detection through campaigns and policies. The introduction of the Hridayasparsham heart health campaign by the Kerala health department in September 2023 is one such government initiative taken to underline the importance of early detection of cardiac disease. This, combined with growing public awareness and acceptance of modern diagnostic tools, places the heart tumor market in a position of sustained growth over the years.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Base Year Market Size (2024) |
USD 1.1 billion |
|
Forecast Year Market Size (2037) |
USD 2.3 billion |
|
Regional Scope |
|
Tumor Type (Primary Tumors and Secondary Tumors)
Primary tumor segment is estimated to hold heart tumor market share of over 81% by the end of 2037. Primary cardiac tumors often require critical imaging and diagnosis for the purpose of treatment. In October 2022, Siemens Healthineers launched a budget-friendly MRI scanner to increase the accessibility of magnetic resonance imaging. The progress made in this area supports the increased demand for diagnostic tests of the primary tumor, as accessible solutions to these tests are offered to healthcare providers.
Treatment (CT Scan, MRI Scan, Nuclear Imaging, Echocardiography)
In heart tumor market, echocardiography segment is set to account for revenue share of more than 51% by the end of 2037, facilitated by the modality's capability for the non-invasive detection of heart tumors. Echocardiography remains a cornerstone in cardiac tumor diagnostics due to its broad accessibility and affordability as a diagnostic modality. In June 2024, Cleerly introduced Cleerly ISCHEMIA, a diagnostic based on coronary computed tomography angiography, underlining the value of imaging tools in cardiac diagnostics. This growing preference for echocardiography underlines its relevance in the market because it is affordable and robust in diagnostic accuracy.
Our in-depth analysis of the market includes the following segments
|
Tumor Type |
|
|
Diagnosis |
|
|
Treatment |
|
North America Market Analysis
By 2037, North America heart tumor market is anticipated to capture over 40% share, due to factors such as improved healthcare infrastructure, greater pervasiveness of cardiovascular diseases, and an increased focus on preventive care. The easy availability of advanced diagnostic tools and reimbursement-friendly policies tends to act as a catalyst for market growth. Additionally, the region’s high rate of R&D investment in medical technology fosters innovation, ensuring ongoing advancements in heart tumor diagnostics.
The U.S. heart tumor market continues to expand at a stable rate due to the rising healthcare expenditure while investing in AI and other imaging technologies for cardiac care. For example, Centaur Pharmaceuticals launched a generic version of Corlanor used for chronic heart failure in July 2024, increasing the availability of medications for heart failure. Such developments reflect the U.S. government's focus on overall cardiac care solutions and further cemented its position as one of the leading markets.
Canada heart tumor market is growing significantly, supported by government-funded healthcare programs and increased adoption of advanced imaging modalities. For example, Health Canada's focus on innovating diagnostic solutions has also placed it in a good market for heart tumor diagnostics. In October 2023, Philips collaborated with Quibim to embed AI-powered imaging software within the Philips HealthSuite Imaging Cockpit platform, enabling access to diagnostic insights for cardiologists and primary care physicians in Canada. These factors combined are likely to strengthen the country's commitment to advancing cardiac diagnostics and imaging.
Asia Pacific Market Analysis
In heart tumor market, Asia Pacific region is poised to showcase growth rate of over 8.5% from 2025 to 2037. Increasing investments in diagnostic infrastructure, along with increased awareness of cardiovascular health, are considered key propellers for this growth. Furthermore, government support for innovative diagnostics and a rise in public awareness of heart health enable the market to offer opportunities to the players. The demand for affordable and efficient diagnostic services also continues to increase with the region's large and aging population, promoted by urbanization trends. This demand is thereby creating a significant scope for global companies in Asia Pacific heart tumor sector.
Increasing awareness about public health and governmental investments in cardiac care infrastructure are some of the major factors contributing to the growth in India heart tumor market. Companies are capitalizing on the available opportunities in the industry through various product launches targeted toward treating heart tumors. For example, Roche Diagnostics India, in April 2024, launched a POCT NT-proBNP test for diabetes patients at risk of heart failure. The test encourages early detection for cardiac care. This initiates a responsible approach by India toward cardiac health, which would contribute to the growth of the market during the forecast period.
Considering the market for heart tumor diagnostics, robust healthcare reforms, and promotion of government policies on advanced imaging solutions, China is one of the largest markets in cardiac disease diagnosis. The early diagnosis of heart disease in China raises demand for innovative diagnostic tools. In April 2023, Siemens Healthineers expanded MRI manufacturing in China to meet the growing demand for advanced medical imaging, demonstrating the country’s commitment to advancements in medical imaging.
Key competitors in the heart tumor market include Koninklijke Philips N.V., GE Healthcare, Siemens Healthineers, Amneal Pharmaceuticals LLC, TomTec Imaging Systems GmbH, Boston Scientific Corporation, and Terumo Cardiovascular Systems Corporation, among others. These players are focusing on research and development into advanced diagnostic imaging technologies and artificial intelligence solutions to make cardiac care more effective and accessible. Furthermore, major companies are aggressively investing in R&D, forming partnerships, and launching new products to reinforce their market positions, especially when demand for innovative diagnostic solutions is rising globally.
In June 2024, Amazon Web Services Inc. invested USD 10 million into research development on pediatric healthcare to significantly improve the way different types of rare diseases, like heart tumors, are dealt with. These investments accelerate technological advances and market growth, enhance the quality of care, and increase access to innovative diagnostic solutions. Furthermore, continuous investments in imaging technologies and partnerships among major players in heart tumor diagnostics enable early diagnosis and outcomes improvement solutions, thereby driving competition in the heart tumor market.
Here are some leading players in the heart tumor market:
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?